Medicines Monitoring Unit-MEMO, University of Dundee, Dundee, UK.
Br J Clin Pharmacol. 2012 Aug;74(2):354-61. doi: 10.1111/j.1365-2125.2012.04195.x.
To understand public and general practitioner (GP) opinion on the acceptability of randomized policy design (RPD) studies (cluster randomized trials) of prescription medicines in Scotland.
We surveyed public opinion on the concept of RPD studies in a sample of 1040 adults to determine acceptability and understand how people feel when changes are made to their medicines. We also surveyed GPs (n = 1034) about the concept of RPD studies as a tool for improving understanding of comparative effectiveness and safety of medicines in the 'usual care' setting.
Thirty per cent of people would be happy to receive a letter about randomized policy changes to their therapy, 31% would not mind or had no opinion and 39% would be unhappy. This view was sensitive to the reason for change; effectiveness and safety reasons were most acceptable (96%) and cost saving least acceptable (39%). Only 19% thought randomized policy change was not an acceptable method of determining the best treatments. Eighty-one per cent of respondents were willing for their medical data to be followed up to compare drug treatments (further 10% undecided). Participants reporting long-term medical conditions and those reporting previous changes to drug therapy were more in favour of RPD studies than other participants. Thirty-three per cent (n = 341) of GPs responded to our survey. Of these, 45% were in favour of RPD studies, 19% were undecided and 36% not in favour.
The public in Scotland is broadly supportive of the concept of randomized policy design studies of medicines, while there is a spread of opinion among GPs.
了解公众和全科医生(GP)对苏格兰处方药物随机政策设计(RPD)研究(整群随机试验)可接受性的看法。
我们在 1040 名成年人中调查了公众对 RPD 研究概念的看法,以确定其可接受性,并了解当他们的药物发生变化时人们的感受。我们还调查了 1034 名全科医生,了解 RPD 研究作为一种工具在“常规护理”环境中提高对药物比较有效性和安全性的理解的概念。
30%的人会很高兴收到关于他们治疗方案随机政策变化的信,31%的人不介意或没有意见,39%的人会不高兴。这种观点对变化的原因很敏感;有效性和安全性的原因最容易被接受(96%),节省成本的原因最不容易被接受(39%)。只有 19%的人认为随机政策变化不是确定最佳治疗方法的可接受方法。81%的受访者愿意让他们的医疗数据得到跟进,以比较药物治疗(另外 10%的人犹豫不决)。报告有长期医疗条件的参与者和报告以前药物治疗发生变化的参与者比其他参与者更支持 RPD 研究。33%(n=341)的全科医生对我们的调查做出了回应。其中,45%的人赞成 RPD 研究,19%的人犹豫不决,36%的人不赞成。
苏格兰公众普遍支持药物随机政策设计研究的概念,而全科医生的意见则存在分歧。